Concentric Capital Strategies LP Invests $12.68 Million in Ralliant Corporation $RAL

Posted by Brenda Bartman on Jun 18th, 2026

Concentric Capital Strategies LP bought a new position in Ralliant Corporation (NYSE:RAL – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 249,146 shares of the company’s stock, valued at approximately $12,684,000. Concentric Capital Strategies LP owned about 0.22% of Ralliant at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Danske Bank A S acquired a new stake in shares of Ralliant in the fourth quarter valued at approximately $25,000. V Square Quantitative Management LLC acquired a new position in Ralliant during the 4th quarter worth $26,000. Allworth Financial LP lifted its holdings in Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after buying an additional 293 shares in the last quarter. Palisade Asset Management LLC bought a new position in Ralliant in the 3rd quarter valued at $26,000. Finally, BOKF NA bought a new position in Ralliant in the 3rd quarter valued at $29,000.

Analysts Set New Price Targets

Several research analysts have recently weighed in on RAL shares. Morgan Stanley upped their price target on shares of Ralliant from $45.00 to $68.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Citigroup upped their target price on shares of Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Truist Financial restated a “buy” rating and issued a $68.00 price target (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Finally, TD Cowen lifted their target price on Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, May 20th. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Ralliant currently has a consensus rating of “Moderate Buy” and a consensus price target of $67.30.

View Our Latest Report on RAL

Ralliant Trading Down 1.8%

Shares of Ralliant stock opened at $67.50 on Thursday. The stock has a market cap of $7.56 billion and a P/E ratio of -6.17. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $70.22. The business’s 50 day moving average is $54.62 and its 200-day moving average is $50.26.

Ralliant (NYSE:RAL – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The business had revenue of $534.60 million for the quarter. The business’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities research analysts predict that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is -1.83%.

About Ralliant

(Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.